Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 17 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
Rail Vision Ltd. (NASDAQ: RVSN) Strengthens Commercial Momentum with Next Phase of Israel Railways Collaboration
Rail Vision, Israel Railways outline next stage of ongoing relationship. The ShuntingYard system is engineered…
-
QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Highlights Revenue Expansion Following $61 Million Veloce Acquisition
SEGG Media (NASDAQ: SEGG, LTRYW) provided an investor update outlining the diversified and expanding revenue streams…
-
QualityStocksNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Featured in NetworkNewsAudio on AI Service Robotics Commercialization
Nightfood Holdings (OTCQB: NGTF) is featured in a NetworkNewsAudio Audio Press Release titled “AI Service…